hronic hypertension is one of the most important modifiable risk factors for stroke and vascular dementia.
C
hronic hypertension is one of the most important modifiable risk factors for stroke and vascular dementia. 1, 2 In the cerebral circulation, vascular remodeling in smaller resistance vessels during chronic hypertension, including hypertrophy and inward remodeling, can be both protective and detrimental. 3 Despite substantial efforts in the past few decades, the molecular mechanisms of vascular remodeling in the cerebral circulation are not completely understood. It is therefore of ultimate importance to study vascular remodeling in smaller resistance vessels to fully understand and provide effective treatment of stroke.
The renin-angiotensin system is activated in chronic hypertension. The system's main effector molecule, angiotensin II (Ang II), plays crucial roles in vascular smooth muscle cell (VSMC) growth and migration, which is critical in hypertrophy and inward remodeling in cerebral arterioles. These functions are mediated, in large part, by the G-protein-coupled angiotensin type 1 receptor (AT 1 R). 4 Although AT 1 R lacks intrinsic tyrosine kinase activity, its activation nevertheless leads to tyrosine phosphorylation of multiple signaling proteins. As an example, AT 1 R has been shown to transactivate epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that can be activated by various growth factors. 5 In addition, Ang II-mediated proliferation and migration of SMC were found to depend on transactivation of EGFR. 6 Also of interest is that Ang II-mediated EGFR transactivation in VSMC requires the presence of reactive oxygen species. 7 We have recently shown that reactive oxygen species generated by Nox2-containing nicotinamide adenine dinucleotide phosphate oxidase are critical in Ang II-induced vascular remodeling in cerebral arterioles. 8 These findings strongly suggest that vascular remodeling in cerebral arterioles might involve Ang II and subsequent production of reactive oxygen species, leading to transactivation of EGFR. Therefore, the first goal in this study was to examine the role of EGFR signaling in Ang II-mediated hypertrophy and inward remodeling in cerebral arterioles using both a genetic model of EGFR point mutation and a pharmacological inhibitor.
Formation of caveolae may play a central role in transactivation of receptor tyrosine kinases by Ang II. Caveolae are plasma membrane microdomains (aka lipid rafts) where Abstract-Angiotensin II (Ang II) is a major determinant of vascular remodeling in the cerebral circulation during chronic hypertension, which is an important risk factor for stroke. We examined the molecular mechanism of Ang II-mediated cerebrovascular remodeling that involves the epidermal growth factor receptor (EGFR) pathway. Mutant EGFR mice (waved-2), their heterozygous control (wild-type [WT]), and C57BL/6J mice were infused with Ang II (1000 ng kg
) or saline via osmotic minipumps for 28 days (n=8 per group). Eight of the Ang II-infused C57BL/6J mice were cotreated with AG1478 (12 mg/kg per day, IP), a specific EGFR tyrosine kinase inhibitor. Systolic arterial pressure was measured by a tail-cuff method. Pressure and diameter of cerebral arterioles were measured through an open cranial window in anesthetized mice. Cross-sectional area of the wall was determined in pressurized fixed cerebral arterioles. Expression of phosphorylated EGFR (p-EGFR), caveolin-1 (Cav-1), and c-Src was determined by western blotting and immunohistochemistry. Mutation of EGFR or AG1478 treatment did not affect Ang II-induced hypertension. Ang II increased the expression of p-EGFR in WT mice, confirming the activation of EGFR. Ang II induced hypertrophy and inward remodeling of cerebral arterioles in WT mice. Hypertrophy, but not remodeling, was prevented in waved-2 and AG1478-treated C57BL/6J mice. Ang II increased p-EGFR, Cav-1, and c-Src expression in WT but not in waved-2 or AG1478-treated C57BL/6J mice. These results suggest that Ang II-induced hypertrophy in cerebral arterioles involves EGFR-dependent signaling and may include Cav-1 and nonreceptor tyrosine kinase c-Src. This signaling pathway seems to be limited to Ang II-induced hypertrophy, but not inward remodeling, and is independent of blood pressure. (Hypertension.
EGFRs, as well as many other signaling molecules, such as c-Src, are compartmentalized, in part, by forming complexes with Cav-1. 9 It has been proposed that the transactivation of EGFR is mediated by AT 1 R trafficking into caveolae. 10 In addition, c-Src, the most abundant subtype of the Src family in the vasculature, has been shown to be essential in Ang II-mediated transactivation of EGFR in VSMC. 11 This c-Srcdependent pathway also relies on the production of superoxide derived from nicotinamide adenine dinucleotide phosphate oxidase. 7 Thus, our second goal in this study was to determine whether Cav-1 and c-Src are involved in EGFR-mediated, Ang II-induced vascular remodeling in cerebral arterioles.
Methods
Materials and Methods are available in the online-only Data Supplement.
Animals
Breeding pairs of female heterozygous and male homozygous waved-2 mice were crossed per recommendation of Jackson Laboratory (Bar Harbor, ME) to generate animals for experimental use (Strain name: STOCK a/a Egfr wa2 /J; stock number: 000317). Waved-2 mice lose ≈90% of EGFR function. 12 These mice have curled hair and vibrissae at young age that disappear later in life and have abnormal aortic valve morphology. Heterozygous littermates (wild-type [WT]) were used as controls. All mice were genotyped before use. C57BL/6J mice were purchased from Jackson Laboratory. Animals were housed in pathogen-free facility at 24°C, exposed to 12 hours of light, and allowed free access of food and fluid. All procedures were approved by Institutional Animal Care and Use Committee of the University of Iowa and in agreement with the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Treatments
To study the effects of EGFR deficiency in a genetic model, WT and waved-2 mice were randomly divided into a treatment group that received Ang II (1000 ng kg −1 min −1
; 28 days) via osmotic minipumps (model 1004; Durect, Cupertino, CA) and a control group that received saline (n=8 per group). In a second set of experiments, the effects of EGFR inhibition were studied using the pharmacological inhibitor AG1478 in C57BL/6J mice that were randomly divided into 2 treatment groups and a control group. The first treatment group (n=10) received Ang II (1000 ng kg
) via osmotic minipumps for 28 days and AG1478 via intraperitoneal injections (12 mg/kg per day; Sigma, St Louis, MO). 13 This dosing regimen was expected to achieve plasma concentrations of AG1478 sufficient to significantly inhibit the activity of EGFR tyrosine kinase.
14 The second treatment group (n=10) received Ang II and injection of vehicle (DMSO diluted in saline). The control group (n=8) received saline via minipump only.
Measurement of Cerebral Arteriolar Pressure and Diameter
We measured pressure and diameter in first-order arterioles on the cerebrum in anesthetized mice through an open-skull preparation that we described previously in detail. 15 
Determination of Cerebral Arteriolar Structure
About 30 minutes after completion of surgery, baseline pressure and diameter of cerebral arterioles were measured. Arterioles were then suffused with artificial cerebrospinal fluid containing ethylenediaminetetraacetic acid (67 mmol/L), which produced maximal dilatation of cerebral arterioles. 16 Cross-sectional area of the arteriolar wall was determined histologically as described previously.
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Statistical Analysis
Differences between groups were determined by Student t test for 2 groups or 1-way ANOVA for ≥3 groups using Graph Pad Prism 6 (Graph Pad Software, San Diego, CA). Values were presented in mean±SEM and were considered different when P<0.05.
Results
Ang II Activates EGFR in Cerebral Arteries
Ang II has been shown to activate EGFR via phosphorylation in VSMC. 6 To determine whether Ang II activates EGFR in cerebral arteries, western blotting of p-EGFR, the active form of EGFR, was performed. Ang II increased the density of p-EGFR in cerebral arteries in WT mice ( Figure 1A ), suggesting Ang II-increased phosphorylation of EGFR. Furthermore, immunohistochemical staining found that Ang II significantly increased the expression of p-EGFR in cerebral arterioles in WT but not in waved-2 mice ( Figure 1B ). Isotype IgG control of p-EGFR confirmed the antibody specificity ( Figure S1 in the online-only Data Supplement). This result confirmed that Ang II activated EGFR in cerebral arterioles in WT mice and suggested that Ang II-induced activation of EGFR expression was attenuated in waved-2 mice.
Ang II Causes Hypertrophy of Cerebral Arterioles Through EGFR
We have previously shown that Ang II is a determinant of hypertrophy in cerebral arterioles. 8 In this study, cross-sectional area of the cerebral arteriolar wall was significantly increased by Ang II in WT (537±41 versus 399±24 μm 2 in saline) but not in waved-2 mice (404±20 versus 418±27 μm 2 in saline; Figure 2 ). To confirm the role of EGFR, we used pharmacological inhibitor of EGFR tyrosine kinase, AG1478 in C57BL/6J mice. AG1478 abolished Ang II-induced increase in cross-sectional area (356±19 versus 527±31 in Ang II alone; Figure 3A) . Furthermore, AG1478 inhibited the Ang II-induced increased expression of p-EGFR in cerebral vasculature ( Figure 3B ). Additional isotype IgG control of p-EGFR confirmed the antibody specificity in C57BL/6J mice ( Figure S1) . These results strongly demonstrate a critical role of EGFR in Ang II-induced cerebral arteriolar hypertrophy.
In addition to hypertrophy, Ang II has been shown to be a determinant of inward remodeling and increased distensibility in cerebral arterioles. 8, 18 In this study, however, mutation or inhibition of EGFR neither affects baseline diameters (Table) nor attenuates the downward shift in the pressure-diameter relationship ( Figure S2 ) observed in maximally dilated cerebral arterioles of Ang II-treated controls, suggesting that activation of EGFR did not contribute significantly to Ang II-mediated inward remodeling. Stress-strain relationship ( Figure S3 ) was not affected by EGFR mutation. Although AG1478 had some effects to slightly left-shifted the curve, collectively wall distensibility was not significantly affected in cerebral arterioles.
Molecular Mechanism of EGFR-Mediated, Ang II-Induced Hypertrophy
Cell culture studies have demonstrated that both Cav-1 and c-Src are important signaling molecules in VSMC growth, 11, 19 which is considered a mechanism for hypertrophy in cerebral arterioles. Protein expression of Cav-1 and c-Src was significantly increased by Ang II in cerebral arteries from WT mice ( Figure 4A ). Moreover, although Ang II also increased the protein expression of Cav-1 and c-Src in EGFR −/− mice, the increase was substantially smaller. Similarly, immunohistochemistry showed that strong staining density of Cav-1 and c-Src in cerebral arterioles was only observed in Ang II-treated WT but not in waved-2 mice ( Figure 4B ). Isotype IgG controls of Cav-1 and c-Src confirmed the antibody specificity ( Figure S1 ). These results support the concept that Cav-1 and c-Src are involved in Ang II-EGFR signaling in hypertrophy of cerebral arterioles.
Deficiency of EGFR Does Not Affect Ang II-Induced Hypertension
Ang II may induce hypertrophy in cerebral arterioles through a direct or an indirect pressor effect. 18, 20 Therefore, it is important to evaluate whether the effect of EGFR inhibition on hypertrophy is pressure dependent. We found that Ang II increased systemic blood pressure comparably between WT and waved-2 mice ( Figure 5) . Similarly, EGFR inhibitor AG1478 did not have significant effect on Ang II-induced hypertension. These results suggested that reduced hypertrophy in cerebral arterioles by EGFR deficiency was not because of a blood pressure-lowering effect.
Discussion
Vascular remodeling is considered an adaptive response in chronic hypertension. Small cerebral arterioles undergo hypertrophy and inward remodeling to protect the vessel wall against increased wall stress. However, these structural changes also have negative effect. For example, smaller lumen diameter may negatively affect the vessel's ability to dilate and increase blood flow when needed. Because chronic hypertension is a major risk factor for stroke, understanding the molecular mechanisms of vascular remodeling induced by increased pressure can be useful for understanding the cause and better treatment of stroke. Therefore, we sought to determine the molecular mechanism of vascular remodeling in small cerebral arterioles, which has substantial vascular resistance and thought to be important for local blood flow control. We have several novel findings; first, we showed that phosphorylation of EGFR was increased in cerebral arterioles from mice treated with Ang II. Second, we demonstrated that EGFR activation was critical in Ang II-induced hypertrophy in cerebral arterioles. EGFR activation, however, did not seem to involve in Ang II-mediated inward remodeling and increased in wall distensibility. Third, Cav-1 and c-Src, signaling molecules that heavily participated in Ang II-induced hypertrophy in VSMC, may be involved in EGFR-dependent hypertrophy in cerebral arterioles. This pathway may be pressure-independent because EGFR mutation or AG1478 did not significantly affect Ang II-induced hypertension. The renin-angiotensin system is activated during chronic hypertension. Ang II, the major effector molecule of the reninangiotensin system, mediates hypertrophy and inward remodeling in cerebral arterioles, which is dependent on reactive oxygen species derived from Nox2-containing nicotinamide adenine dinucleotide phosphate oxidase. 8, 15 We examined the role of EGFR in this study because previous studies in VSMC cultures showed that reactive oxygen species were critical in transactivation of EGFR. We demonstrated that Ang II increased the protein expression of p-EGFR. Ang II-induced hypertrophy in cerebral arterioles was inhibited by EGFR mutation or AG1478. These results strongly suggest, for the first time, that EGFR activation is essential in Ang II-mediated cerebral arteriolar hypertrophy. In contrast, EGFR was not involved in Ang II-mediated inward remodeling, which supports the idea that molecular mechanisms of hypertrophy and inward remodeling are distinctive and independent. 15, 21 The process through which Ang II transactivates EGFR in VSMC is known to involve multiple signaling events beginning with activation of AT 1 R. 22 Once activated, AT 1 R migrates into Cav-1-rich caveolae along with several other signaling molecules, including Cav-1, EGFR, c-Src, and cAbl. 19 This recruitment process seems to be reactive oxygen species dependent. 10 The end result is that Cav-1 acts as a scaffold protein that brings together the signaling events through which Ang II leads to EGFR transactivation. Based on these findings in VSMC, we sought to determine whether Cav-1 and c-Src are also involved in Ang II-induced transactivation of EGFR and hypertrophy in cerebral arterioles. We found that Ang II increased the expression of Cav-1 and c-Src in WT but not in waved-2 mice, which suggests that these signaling molecules indeed may play a role in Ang II-induced cerebral arteriolar hypertrophy. Although how Cav-1 is involved in this signaling pathway is not known, the result of this study may suggest that Cav-1 has pro-proliferation properties in cerebral arterioles. Although Ang II may induce cerebral vascular hypertrophy through an AT 1 R-dependent mechanism independently of its pressor effect, one must consider the possibility that a pressordependent mechanism also contributed to our finding in this study of Ang II. 20 In this study, we found that EGFR mutation or AG1478 treatment did not blunt the pressor effect of Ang II, but nevertheless prevented Ang II-mediated hypertrophy.
Previous studies showed that AG1478 either unchanged or decreased the blood pressure in anesthetized rats. 23, 24 Because inhibition of EGFR did not affect blood pressure in this study, it is more likely that Ang II mediates hypertrophy through a direct AT 1 R-EGFR-dependent pathway, rather than other indirect mechanisms.
It is noteworthy that although genetic mutation or AG1478 did not affect hypertension induced by 4-week treatment of Ang II in this study, previous studies showed that other means of EGFR inhibition reduced systemic blood pressure in different animal models, suggesting that EGFR may be involved in blood pressure regulation under particular conditions. For example, hypertension induced by a lower dose of Ang II for 2 weeks was reduced by ≈15 mm Hg by EGFR antisense in rats. 25 Another study showed that a different pharmacological EGFR inhibitor, PKI-166, reduced the blood pressure in nephrectomized rats after 8 weeks. 26 A few limitations in this study are noteworthy. First, we were not able to detect the pressor effect of Ang II in cerebral arterioles (Table) although an increase was observed in systemic pressure. The likely explanation for this apparent discrepancy is that systemic pressure was measured in unanesthetized mice using the tail-cuff method, whereas cerebral arteriolar pressure was measured in anesthetized mice using a servo-null system. Anesthesia is known to lower blood arterial pressure in mice and blunt responses to pressor agents. 27 Despite this, the evaluation of long-term structural changes in cerebral arterioles by Ang II should not be affected under this condition. Second, the use of western blotting to determine protein expression of p-EGFR, Cav-1, and c-Src was limited to larger cerebral arteries because cerebral arterioles contain insufficient amounts of protein. However, we have further confirmed the expression and location of these proteins in cerebral arterioles using immunohistochemistry. Third, although Cav-1 and c-Src may be important signaling molecules, further studies are needed to determine exactly how these proteins interact within the signaling pathway of Ang II-EGFR-dependent hypertrophy.
Perspectives
Ang II is a major mediator of vascular structural changes in cerebral arterioles during chronic hypertension, which is one of the most important risk factors for stroke. The molecular mechanism of this process, however, is not completely understood. EGFR-dependent signaling is likely involved in Ang II-mediated cerebral arteriolar hypertrophy but not inward remodeling. Cav-1 and c-Src may also be involved and deserved more in-depth investigations.
Methods
Determination of systemic blood pressure
Systemic blood pressures were measured in conscious mice using an automated tail-cuff device (Visitech Systems BP-2000, Apex, NC). Mice were placed in mouse holders that allow measurement of systolic blood pressure under resting conditions. Mice were trained for 5 days, then blood pressure was measured after 0 (baseline), 7, 14, 21, 28 days of treatment. Each day 30 measurements were made and averaged for each mouse.
Measurement of cerebral arteriolar pressure and diameter
After the treatment period, animals were anesthetized with ketamine/xylazine (87.5/12.5mg/ml, 10ml/kg,i.p.). Supplementary anesthetic (pentobarbital sodium, 50mg/ml) was given during the experiment through a catheter connected to the femoral vein. We measured pressure and diameter in first-order arterioles on the cerebrum through an open skull preparation. Cerebral arteriolar systolic, diastolic, mean, and pulse pressure were measured continuously with a micropipette connected to a servo-null pressure-measuring device (model 5, Instrumentation for Physiology and Medicine, Inc). Arterioles were monitored through a microscope connected to a closed-circuit video system with a final magnification of x356. Arteriolar diameter was measured from digitized images of arterioles using NIH Image J (NIH, Bethesda, MD).
Determination of cerebral arteriolar structure
About 30 minutes after completion of surgery, baseline pressure and diameter of cerebral arterioles were measured. Arterioles were then suffused with artificial cerebrospinal fluid containing ethylenediaminetetraacetic acid (EDTA, 67 mmol/L), which produced maximal dilatation of cerebral arterioles. Pressure-diameter relationships were obtained in deactivated cerebral arterioles between cerebral pressures of 40 and 10 mmHg. Arterioles were then fixed at physiological pressure in vivo by suffusion with glutaraldehyde fixative (2.25% glutaraldehyde in 0.10 mol/L cacodylate buffer) while maintaining cerebral arteriolar pressure at baseline levels. After mice were euthanized using overdose sodium pentobarbital, the arteriolar segment was removed, processed and embedded in Spurr's low viscosity resin while maintaining crosssectional orientation. Cross-sectional area of the arteriolar wall was determined histologically.
Western blotting of p-EGFR, EGFR, Cav-1, and c-Src
Protein expression of EGFR, phosphorylated EGFR (p-EGFR), Cav-1 and c-Src was measured in cerebral arteries using western blotting in WT and waved-2 mice with or without AngII. Cerebral artery segments were excised, snapped frozen in liquid nitrogen, and homogenized in Laemmli buffer over liquid nitrogen. Multiple arterial segments were pooled to obtain a sufficient amount of protein for blotting. Protein concentrations were determined using the Bradford protein assay kit (Bio-Rad, Hercules, CA). Equal quantities of protein were loaded onto a 15% (Cav-1) or 10% (all other proteins) polyacrylamide electrophoresis gel. After electrophoresis (110 V, 90 min), the separated proteins were transferred to nitrocellulose membrane (Bio-Rad). Membranes were blocked in 5% skim milk in Tris buffered saline tween 20 for 1 hour and then incubated overnight (4 °C) with actin (1:2000; Cell Signaling, Danvers, MA), EGFR, p-EGFR (1:1000; Santa Cruz, Dallas, TX) , Cav-1 (1:1000; BD Bioscience, San Jose, CA), c-Src (1:1000; Invitrogen, Grand Island, NY) primary antibodies in 5 % skim milk. Membranes were then incubated with the corresponding horseradish peroxidase-conjugated with anti-rabbit and antimouse IgG secondary antibodies for 1h (1:2500, room temperature). Immunoreactive bands were
